Close

BioMarin Pharma (BMRN) Presents Updated Vosoritide Phase 2 Data in Achondroplasia; Mean Annualized Growth Velocity Similar to Lower Dose

Go back to BioMarin Pharma (BMRN) Presents Updated Vosoritide Phase 2 Data in Achondroplasia; Mean Annualized Growth Velocity Similar to Lower Dose

BioMarin Presents Vosoritide Data in Achondroplasia at American Society of Human Genetics (ASHG) 2016 Meeting

October 19, 2016 5:01 PM EDT

Highest Dose (30 µg/kg/day) Shows Approximately 50% Increase in Mean Annualized Growth Velocity, Comparable with 15 µg/kg/day dose

Consistent Safety Profile at High Dose

Findings Support 15 µg/kg/day in Phase 3, Randomized Controlled Study to Start by End of 2016

SAN RAFAEL, Calif., Oct. 19, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today provided an update on its Phase 2 study of vosoritide, an analog of C-type Natriuretic Peptide (CNP), in children with achondroplasia, the most common form of dwarfism, at the American Society of... More